zurück Home

Ovarial - Karzinom: Studien
allgemeines Klinische Studien sind die wichtigste Erkenntnisquelle für Therapieentscheidungen.
Operation
AGO-OVAR OP.4 / AGO DESKTOP OVAR III A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery versus Chemotherapy alone for Recurrent Platinum-Sensitive Ovarian Cancer Studie offen, Studienleiter Dr. Philipp Harter
LION Die systematische pelvine und paraaortale Lymphonodektomie bei klinisch unverdächtigen LKs verbessert die Prognose epithelialer Ovarialkarzinome im Stadium IIB-IV nicht signifikant!
DESKTOP III AGO-Ovar OP.4; ENGOT-ov20; NCT01166737 OP besser als keine OP
Chemotherapie
Taxol GOG 158, GOG 162, GOG 111 Caelyx EORTC 55051, CALYPSO MITO-2
Hycamptin: HECTOR Hochdosis: GOG 164
intraperitoneale Chemotherapie: GOG 172 Erhaltungstherapie: ABAGOVO-MAB/OVAR 10
praeoperative Chemotherapie: EORTC 55971 Rezidiv - Chemotherapie: MRC OV05/EORTC 55955
Targettherapie
Bevacizumab OCEANS OVAR 11 GOG 0218ICON 7
Erlotinib EORTC 55041
PARP Inhibitor GOG-280 ENGOT-OV16/NOVA
MEK-IH Selumetinib GOG-239 (9,10) MEK162 MILO
Tie2 - Ang1, -Ang2 -IH AMG386 - Trial
Immun-Modulation
Tamoxifen versus Thalidomid GOG-198 GOG-198 Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular en. Gynecol Oncol 119: 444-50, 2010. Hurteau JA, Brady MF, McGuire WP, Edmonds P, Darcy KM, Pearl ML, Ivanov I, Tewari K, Mannel RS, Zanotti K, Benbrook DM  
Endokrine Therapie
Tamoxifen NSGO-OC-0101 Tamoxifen 40mg/d versus Caelyx oder Taxol weekly: PFS: Chemotherapie besser, OS: nicht signifikant!
GOG-198 GOG-198 Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular en. Gynecol Oncol 119: 444-50, 2010. Hurteau JA, Brady MF, McGuire WP, Edmonds P, Darcy KM, Pearl ML, Ivanov I, Tewari K, Mannel RS, Zanotti K, Benbrook DM  
 
Histologie
GOG 187 Stromazelltumoren Cisplatin + Paclitaxel
GOG-251 (8) Rezidivierende Sex Cord Stromal Ovarian Tumors Bevacizumab shows activity in treating recurrent sex cord stromal ovarian tumors. Brown J, Brady W, Schink J, Van Le L, Leitao M, Yamada SD, De Geest K, Gershenson D 2012
AGO ROBOT Borderline - Tumoren Sammelstudie mit 1236 Fällen  
genetisches Risiko GOG 199 Salpingo-Oophorektomie bei genetisches Risiko von Ovarialkarzinom
Quellen 1.) Kristensen G, et al.:
Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.
JCO 29(2011 suppl): Abstr LBA5006

2.) Aghajanian C, et al.:
OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).
JCO 29(2011 suppl): Abstr LBA5007

3.) Karlan BY, et al.:
Randomized, double-blind, placebo-controlled phase 2 study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
JCOncol 30(2012):362–371.

4.) Pfisterer J, et al.:
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
JCO 24(2006):4699-707.

5.) Markman M, et al.:
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.
Gynecol Oncol 114(2009):195-8.

6.) Ozols RF, et al:
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study.
JCO 21(2003):3194-3200

7.) du Bois A, et al:
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
JNCI 95(2003):1320-1329

8.) Brown J, et al.:
Bevacizumab shows activity in treating recurrent sex cord stromal ovarian tumors: results of a phase II trial of the Gynecologic Oncology Group.
Gynecol Oncol 125(2012): 771-3

9.) Farley J, et al.:
A phase II trial of selumetinib (AZD6244) in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Lancet Oncol 14(2013):134-40

10.) Farley J, et al.:
A phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum.
Int J Gynecol Can 21(12): S1-S1372, 2011. (Abstract)

blauer Punkt

Impressum                           Zuletzt geändert am 06.03.2016 21:30